Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Rises By 157.2%

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 649,057 shares, a growth of 157.2% from the December 15th total of 252,374 shares. Based on an average daily volume of 3,554,772 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.9% of the company’s stock are short sold. Approximately 0.9% of the company’s stock are short sold. Based on an average daily volume of 3,554,772 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jyong Biotech stock. Millennium Management LLC purchased a new stake in Jyong Biotech Ltd. (NASDAQ:MENS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,013 shares of the company’s stock, valued at approximately $512,000.

Jyong Biotech Trading Up 0.9%

Shares of NASDAQ:MENS traded up $0.03 during trading on Thursday, hitting $3.46. The stock had a trading volume of 413,510 shares, compared to its average volume of 377,111. Jyong Biotech has a 12-month low of $2.60 and a 12-month high of $67.00. The stock has a 50-day simple moving average of $18.75 and a two-hundred day simple moving average of $32.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.